openPR Logo
Press release

Respiratory Syncytial Virus (RSV) Therapeutics Market 2024-2033: Future Outlook, Global Trends, Industry Share And Top Key Players

04-24-2024 07:39 AM CET | Health & Medicine

Press release from: The Business Research Company

Respiratory Syncytial Virus (RSV) Therapeutics Market

Respiratory Syncytial Virus (RSV) Therapeutics Market

The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $1.27 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 25.2%. The growth in the historic period can be attributed to disease awareness, advancements in virology, pediatric vulnerability, epidemic outbreaks, vaccine development.

The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $3.69 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to biologic therapies innovation, emerging antivirals, focus on elderly population, maternal immunization strategies, global research collaborations. Major trends in the forecast period include monoclonal antibodies advancements, nasal vaccines and delivery systems, combination therapies, novel drug delivery systems, home-based treatment options.

Market Overview -
Respiratory syncytial virus (RSV) therapeutics refers to the treatments and medications employed to manage and treat infections caused by the respiratory syncytial virus. Respiratory syncytial virus is a common respiratory virus that can cause mild to severe respiratory illness, particularly in infants, young children, older adults, and individuals with weakened immune systems.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp

The Rise In The Prevalence Of Rsv Infection
The rise in the prevalence of RSV infection is driving the growth of the respiratory syncytial virus (RSV) therapeutics market going forward. RSV is a prevalent respiratory illness that can result in mild to severe respiratory infections, especially in newborns, young children, elderly adults, and people with compromised immune systems. Increasing RSV infections prompt the development of innovative treatments to address the rising need and mitigate the severity of RSV-related complications. For instance, in September 2022, according to the article published by The Lancet, a UK-based book and periodic data publishing organization, around 11,255 new cases of RSV were recorded in the 2021 summer, which is 9.50% more compared to 10,280 cases in winter 2020-21. Therefore, the rise in the prevalence of RSV infection propels the growth of the respiratory syncytial virus (RSV) therapeutics market.

Competitive Landscape -
Major companies operating in the respiratory syncytial virus (rsv) therapeutics market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd

Pfizer's Abrysvo Approval Marks A Significant Advancement In Respiratory Syncytial Virus (RSV) Therapeutics
Developing new drugs and vaccines with better efficacy is a key trend gaining popularity in the respiratory syncytial virus (RSV) therapeutics market. Major companies operating in the respiratory syncytial virus (RSV) therapeutics market are focused on developing new drugs and vaccines to sustain their position in the market. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, received approval from the Food and Drug Administration, a US-based federal agency responsible for protecting and promoting public health, for ABRYSVO. The bivalent RSV prefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is administered to prevent lower respiratory tract sickness caused by RSV in people 60 and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties, and it has been clinically proven to be safe and productive.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

Key Segments -
The respiratory syncytial virus (rsv) therapeutics market covered in this report is segmented -
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Respiratory Syncytial Virus (RSV) Therapeutics Market 2024-2033: Future Outlook, Global Trends, Industry Share And Top Key Players here

News-ID: 3474188 • Views:

More Releases from The Business Research Company

Segment Evaluation and Major Growth Areas in the Personalized Testing and Supplements Market
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future. Market Valuation and Expansion Forecast for Personalized Testing
Top Players and Market Competition in the Skin Microbiome Industry
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry. Projected Expansion in the Skin
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market Landscape
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory. Steady Growth Expected in Upadacitinib Market Size Through 2029 The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Market
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field. Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics

All 5 Releases


More Releases for RSV

The Rise In The Prevalence Of RSV Infection : A Key Catalyst Accelerating Global …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Respiratory Syncytial Virus (RSV) Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market encompassing therapeutics for respiratory syncytial virus (rsv) has witnessed substantial, rapid expansion lately, projected to increase its valuation from $1.6 billion in 2024 to $2 billion just one year later
The Rise In The Prevalence Of RSV Infection : Transformative Forces Shaping the …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Respiratory Syncytial Virus (RSV) Therapeutics Industry Market Size Be by 2025? The market size for therapeutics treating the respiratory syncytial virus (RSV) has seen significant expansion in the past few years. It is expected to surge from $1.6 billion in 2024 to $2 billion in 2025,
RSV Vaccine Market To Reach 731 million by 2040, Due To Increasing Awareness on …
According to our latest market report "RSV Vaccine Market, Till 2040 by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions and Leading Players", the RSV Vaccine market size is projected to reach USD 731 million by 2040 from USD 1,149 million in current year, during the forecast period. To request quote of this report, please visit: https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-quote.html In the dynamic landscape of preventive therapies for respiratory
Global RSV Diagnostic Products Market Size & Trends
According to a new market research report published by Global Market Estimates, the global RSV diagnostic products market is expected to grow at a CAGR of 11.4% from 2023 to 2028. Ongoing advancements in diagnostic technologies, specifically PCR and rapid point-of-care testing, play a crucial role. These advancements offer heightened accuracy, faster results, and increased accessibility, enabling prompt and precise identification of RSV infections. Browse 147 Market Data Tables and 115 Figures
Respiratory Syncytial Virus (RSV) Therapeutics Market Size to Reach USD 9080.84 …
Respiratory Syncytial Virus (RSV) Therapeutics Market Scope & Overview Respiratory Syncytial Virus (RSV) Therapeutics Market size was USD 1040.65 Million in 2022 and is expected to Reach USD 9080.84 Million by 2030 and grow at a CAGR of 31.1% over the forecast period of 2023-2030. The Respiratory Syncytial Virus (RSV) Therapeutics market is a vibrant, fiercely competitive sector that is essential to digital marketing. The demand for effective has increased as companies
Respiratory Syncytial Virus (RSV) Therapeutics Market - Conquering RSV: Advancin …
Newark, New Castle, USA: The "Respiratory Syncytial Virus (RSV) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.growthplusreports.com/report/respiratory-syncytial-virus-rsv-therapeutics-market/8519 This latest report